Fig. 1

RBMS3 was downregulated in human breast tumors and correlated with poorer prognosis. a RBMS3 was downregulated in breast cancer cells. The expression levels of RBMS3 in breast cancer cell lines SKBR3, MDA-MB-231, MDA-MB-453, SUM-1315 and ZR75–1 were detected by Western blot and qRT-PCR, and the non-tumorigenic cell line MCF-10A were used as control. b RBMS3 expression was lower in breast cancer tissues. qRT-PCR and western blot were used to detect the expression of RBMS3 in breast cancer tissues and the corresponding adjacent tissues (Reviewer #1 comment 4). The expression of RBMS3 in breast cancer tissues were normalized to the corresponding adjacent tissues. c Expression of RBMS3 in the TCGA Breast Cancer (BRCA) database, including 1247 samples, p<0.001.(Reviewer #1 comment 2) (d) Kaplan-Meier overall survival curve exhibited patients with breast cancer expressing high (red) levels of RBMS3 had better prognosis than those low (black) levels of RBMS3. Including 3955 samples, P < 0.05 by log rank test (Reviewer #1 comment 2). The Affymetrix ID of RBMS3 is 206767_at. (Reviewer #2 comment 2) (e) RBMS3 was downregulated in the four subtypes of breast cancer compared to normal